[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"binge-eating-disorder-associated-with-obesity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:binge-eating-disorder-associated-with-obesity":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053868","halo-trial-high-medium-and-low-intensity-psychotherapy-for-binge-eating-disorder-100053868",false,"NCT07698132","HALO-TRIAL: High, Medium And LOw Intensity Psychotherapy for Binge Eating Disorder","HALO","Inclusion Criteria:\n\n* Binge Eating Disorder according to DSM-5 criteria\n* 18-65 years of age\n* Fluent Danish speaker\n\nExclusion Criteria:\n\n* Concurrent psychotherapeutic treatment\n* Use of weight loss medications within the last month (i.e., GLP-1 receptor antagonists)\n* Suicidal ideation or suicidality\n* Psychosis or psychotic disorders\n* Mania or bipolar disorder\n* Drug misuse disorder\n* Alcohol misuse disorder\n* Cluster B personality disorders in the severe range (diagnosed)\n* Dosage of Antidepressants, Antipsychotics and Stimulants must be stable for at least 6 months","ALL","18 Years","65 Years",{"count":20,"type":21},256,"ESTIMATED","INTERVENTIONAL",[24],"NA","The HALO trial is designed as a four-armed, assessor-blinded, fidelity-monitored randomized clinical trial. The goal of this randomized controlled study is to investigate the effectiveness of four different psychotherapy programs and to determine which one is most effective in reducing the number of binge-eating episodes in people with the eating disorder Binge Eating Disorder (BED), by directly comparing three intensities of Cognitive Behavioral Therapy-Enhanced against a manualized treatment as usual.\n\nParticipants will be asked to complete a 21-weeks randomized intervention and participate in follow up assesments.",[27,28,29,30,31,32,33,34,35],"Binge Eating Disorder","Binge Eating Episodes","Binge Eating\u002FLoss of Control Eating","Binge Eating Disorders","Binge Eating","Binge Eating Behaviour","Binge Eating Disorder Associated With Obesity","Eating Disorder Binge","Eating Disorders",[27,35,37,38,39,40],"Cognitive Behavioral Therapy","Psychotherapy","Randomized Controlled Trial","Evidence-based Psychiatry","RECRUITING","2026-07-07",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":45},"2024-06-10",{"date":49,"type":21},"2032-12",{"name":51,"class":52},"Herlev and Gentofte Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":53},"100596224","behavioral-therapy-and-glp-1-analogue-effects-on-binge-eating-weight-and-coping-in-obesity-100596224","NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","BETTER-GLP1","Inclusion criteria\n\n1. Severe obesity defined as BMI \\>40 kg\u002Fm2 or 35 kg\u002Fm2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome\n2. Age between 18 to 65 years\n3. Diagnosis of BED according to DSM-5 criteria\n4. Willingness to participate and provide informed consent\n5. Able to understand and communicate in Norwegian\n\nExclusion criteria\n\n1. Pregnant or lactating women, as well as women planning pregnancy within one year.\n2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)\n3. Renal failure with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1,73m2\n4. Liver failure with either ASAT and\u002For ALAT 5 times upper reference limit, or ALP and\u002For GT more than 3 times upper reference limit, or clinical signs of liver decompensation\n5. Active cancer\n6. Previous medullary thyroid cancer\n7. Previous pancreatitis\n8. Active substance abuse (but previous drug abuse accepted)\n9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.\n10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program\n11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and\u002For quality of study data.\n12. Previous bariatric surgery\n13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and\u002For naltrexone\u002Fbupropion) within the last 6 months\n14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion",{"count":63,"type":21},80,"OBSERVATIONAL","This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.\n\nThe primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.\n\nAdult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.\n\nChanges in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.",[33,27,34,35,67,68,69],"GLP-1","CBT","Obesity &Amp; Overweight","2025-09-09",{"date":72,"type":45},"2025-09-15",{"date":74,"type":45},"2025-07-01",{"date":76,"type":21},"2028-12-31",{"name":78,"class":52},"Haukeland University Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":53},"100578943","phase-1-a-self-guided-mobile-intervention-for-adults-with-binge-eating-and-obesity-100578943","NCT06817863","A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity","Inclusion Criteria:\n\n1. Are English speaking male or female\n2. Are aged 18-70 years\n3. Have recurrent objective or subjective binge eating episodes (≥12 episodes in 3 months)\n4. Have BMI ≥30\n5. Own an iPhone with iOS 11 or higher, or Android with OS 8.1 or higher\n6. Are willing and able to complete enrollment procedures\n7. Are able to understand the nature of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Are unable to fluently speak, write and read English.\n2. Are already receiving treatment for an eating disorder (e.g., research participants cannot be receiving concurrent eating disorder treatment from another provider)\n3. Are receiving weight loss treatment (behavioral or pharmacological)\n4. Have a mental handicap or are currently experiencing severe psychopathology that would limit their ability to engage in study (e.g., imminent or high risk for suicide, substance use disorder, active psychotic disorder,)\n5. Are purging and\u002For using laxatives 3 or more times per week and are not deemed safe for remote treatment by a primary care provider.\n6. Are exercising 2 or more hours a day on average, or engaging in significantly harmful compensatory behaviors (i.e., \\> 3x\u002Fweek of self-induced vomiting or laxative use), and are not deemed safe for remote treatment by a primary care provider.\n7. Are fasting for 24 hours or more, \\> 3x times a week, and are not deemed safe for remote treatment by a primary care provider.\n8. Are unwilling to receive medical clearance and\u002For medical monitoring as requested by the study to ensure they are medically safe to participate.\n9. Are pregnant or planning to become pregnant within the next year.\n10. Are individuals who are not yet adults (infants, children, teenagers) Are currently taking any of these medications: Haldol, Loxitane, Mellaril, Moban, Navane, Prolixin, Serentil, Stelaxine, Trilafon, Thoraxine, Abilify, Clozaril, Geodon, Risperdal, Seroquel, Zyprexa\n11. Are adults unable to consent\n12. Are prisoners","70 Years",{"count":87,"type":21},30,[89,90],"PHASE1","PHASE2","The proposed study is an open label, non randomized, waitlist controlled single group feasibility study of the feasibility and usability of a digital intervention (called ChangeBite) to be used by individuals with obesity and comorbid binge eating behavior. The proposed research will include approximately 30 participants. Participants will be recruited for this single group pilot trial using online advertising to attend a virtual screening session. Screened participants willing and eligible to participate, will receive informed consent and formally start ChangeBite. Participants will be instructed to engage with ChangeBite and attend follow up assessments on scheduled video calls. Feasibility and acceptability of implementation will be assessed by collecting data on recruitment, retention, usability and satisfaction. The research team will also collect assessment data from participants on feasibility, and usability. In addition to self report scales, semi-structured interviews will be completed with a trained research team member via video call and will be partially recorded. Assessments will be done at baseline, 12 weeks, and 24 weeks. Participants' app use frequency and duration will be tracked using software analytics. Participants' body weight will be captured weekly using a timestamped picture of their weight as it appears on their scale and Body Mass Index will be calculated with these data points.",[33,27],[94,95,96],"digital treatment","self-help intervention","binge eating","2025-02-13",{"date":99,"type":45},"2025-02-17",{"date":101,"type":21},"2025-02",{"date":103,"type":21},"2025-12",{"name":105,"class":52},"Drexel University"]